These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10133464)

  • 1. Getting the most out of low-dose syringe prefilling of a high-cost biotechnology agent.
    Lu A; Chan L
    Hosp Pharm; 1994 Apr; 29(4):353, 356-7. PubMed ID: 10133464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sterility of unit dose syringes of filgrastim and sargramostim.
    Singh RF; Corelli RL; Guglielmo BJ
    Am J Hosp Pharm; 1994 Nov; 51(22):2811-2. PubMed ID: 7531941
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of seven methods of preparing and administering cefazolin sodium small-volume injections.
    Smith TF; Kitrenos JG
    Am J Hosp Pharm; 1986 Aug; 43(8):1930-5. PubMed ID: 3752132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation and cost analysis of a syringe pump system for intermittent i.v. drug delivery.
    Colangelo A; Clark ST; Janousek JP
    Am J Hosp Pharm; 1985 Mar; 42(3):581-4. PubMed ID: 3985021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adsorption of (99m)Tc-radiopharmaceuticals onto injection vials and syringes.
    Mushtaq A; Ur Rehman T; Safdar Mansur M; Jehangir M
    J Nucl Med Technol; 2008 Jun; 36(2):91-4. PubMed ID: 18483140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost comparison of two systems for intermittent intravenous administration of small-volume injections.
    Reilly RT; Strand LM; Bair JN
    Am J Hosp Pharm; 1985 Feb; 42(2):323-8. PubMed ID: 3976678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis of mixing clindamycin and aminoglycosides.
    Abel SR; Olson SM
    Am J Hosp Pharm; 1987 Jun; 44(6):1385-7. PubMed ID: 3618617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost savings realized by use of the PhaSeal(®) closed-system transfer device for preparation of antineoplastic agents.
    Edwards MS; Solimando DA; Grollman FR; Pang JL; Chasick AH; Hightman CM; Johnson AD; Mickens MG; Preston LM
    J Oncol Pharm Pract; 2013 Dec; 19(4):338-47. PubMed ID: 23975556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost analysis of using premixed frozen versus hospital-reconstituted cefazolin sodium injection.
    Havlovic DA; Ivey MF; Grotzinger RP
    Am J Hosp Pharm; 1987 Apr; 44(4):783-7. PubMed ID: 3578311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative costs of anesthesiologist prepared, hospital pharmacy prepared and outsourced anesthesia drugs.
    Jelacic S; Craddick K; Nair BG; Bounthavong M; Yeung K; Kusulos D; Knutson JA; Somani S; Bowdle A
    J Clin Anesth; 2017 Feb; 36():178-183. PubMed ID: 28183562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in an intensive treatment program for children with Ewing's sarcoma.
    Luksch R; Massimino M; Cefalo G; Lombardi F; Ferrari A; Casanova M; Gandola L; Terenziani M; Spreafico F; Fossati-Bellani F
    Haematologica; 2001 Jul; 86(7):753-60. PubMed ID: 11454532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G-CSF (Granulocyte Colony-Stimulating Factor): follow-up and use in a French University hospital.
    Furet I; Closson V; Madelaine I; Faure P
    Can J Hosp Pharm; 1995 Apr; 48(2):90-7. PubMed ID: 10142843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing high cost and biotech drugs: two institutions' perspectives.
    Dana WJ; McWhinney B
    Hosp Formul; 1994 Sep; 29(9):638-45. PubMed ID: 10137060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Financial assessment of device for the preparation of intravenous mixtures in hospital pharmacy].
    Casado Collado A; Luengo Pascual L; Herdman M; Bonafont Pujol X; Clemente Bautista S; Jódar Masanés R; Napal Lecumberri V; Serrano Padilla G
    Farm Hosp; 2004; 28(4):243-50. PubMed ID: 15369434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Justification of a pharmacy intravenous admixture service in an Australian hospital.
    Plumridge RJ; Maher M
    Am J Hosp Pharm; 1993 Mar; 50(3):463-6. PubMed ID: 8442462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-reduction strategy for isoproterenol use in radiofrequency catheter ablation procedures.
    Parkin SR; Negrelli JM; Van Gorder CM; Brooks TWA
    Am J Health Syst Pharm; 2019 Apr; 76(8):551-553. PubMed ID: 31420984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost of tetanus toxoid injection using a jet-injector (Imule) in collective immunization in Senegal: comparison with injection using a syringe and resterilizable needle].
    Schlumberger M; Châtelet IP; Lafarge H; Genêt A; Gaye AB; Monnereau A; Sanou C; Diawara L; Gueye Y; Lang J
    Sante; 1999; 9(5):319-26. PubMed ID: 10657777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purchasing premixed products.
    Geberbauer CW
    J Healthc Mater Manage; 1988; 6(2):40, 42, 44-5. PubMed ID: 10286278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
    Dinçol D; Samur M; Pamir A; Sencan O; Akbulut H; Yalçin B; Onur H; Demirkazik A; Senler FC; Içli F
    Cancer; 2000 May; 88(9):2033-6. PubMed ID: 10813713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.